Unaccepted RSU grant corrected for Bioventus (NASDAQ: BVS) director

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.

Bioventus Inc. filed an amended insider report for director Philip G. Cowdy to correct a previously reported grant of 2,700 Restricted Stock Units dated April 1, 2021. A footnote explains the earlier Form 4 was filed inadvertently for RSUs that were not accepted, and that as of April 1, 2021, Cowdy held no non-derivative or derivative securities of Bioventus.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cowdy Philip G.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	2,700	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct)

Footnotes (1)

On April 5, 2021, the Issuer inadvertently filed a Form 4 reporting a grant of restricted stock units that were not accepted by the Reporting Person. As of April 1, 2021, the Reporting Person held no non-derivative or derivative securities of the Issuer. None.

Key Figures

Reported RSU grant: 2,700 units RSU grant price: $0.0000 per unit Shares after transaction: 0 shares

3 metrics

Reported RSU grant 2,700 units Restricted Stock Units tied to Class A Common Stock, April 1, 2021

RSU grant price $0.0000 per unit Transaction price per Restricted Stock Unit for the reported grant

Shares after transaction 0 shares Total securities held following the corrected transaction as of April 1, 2021

Key Terms

Restricted Stock Units, Form 4, non-derivative, derivative securities

4 terms

Restricted Stock Units financial

"reporting a grant of restricted stock units that were not accepted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Form 4 regulatory

"the Issuer inadvertently filed a Form 4 reporting a grant"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"held no non-derivative or derivative securities of the Issuer"

derivative securities financial

"held no non-derivative or derivative securities of the Issuer"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Form 4 Insider Transactions: What Each Field Means →

04/14/2026 - 06:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cowdy Philip G.

(Last)

(First)

(Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM

NORTH CAROLINA

27703

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2021

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/05/2021

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units⁽¹⁾	⁽²⁾	04/01/2021		A		2,700		⁽²⁾	⁽²⁾	Class A Common Stock	2,700	$0	0	D

Explanation of Responses:

1. On April 5, 2021, the Issuer inadvertently filed a Form 4 reporting a grant of restricted stock units that were not accepted by the Reporting Person. As of April 1, 2021, the Reporting Person held no non-derivative or derivative securities of the Issuer.

2. None.

Remarks:

	/s/ Anthony D'Adamio, Attorney-in-Fact	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Bioventus (BVS) Form 4/A for Philip G. Cowdy correct?

The Form 4/A corrects an earlier filing that mistakenly reported a grant of 2,700 Restricted Stock Units. A footnote states the RSUs were not accepted and clarifies that, as of April 1, 2021, Cowdy held no Bioventus securities.

How many Bioventus (BVS) Restricted Stock Units were originally reported for Philip G. Cowdy?

The original filing reported a grant of 2,700 Restricted Stock Units tied to Bioventus Class A Common Stock. The amendment explains this grant was reported inadvertently and was not accepted, so it did not result in any actual holdings.

Does Philip G. Cowdy hold any Bioventus (BVS) shares after this Form 4/A?

According to the footnote, as of April 1, 2021, Philip G. Cowdy held no non-derivative or derivative securities of Bioventus. The amended filing is intended to correct a prior erroneous report of an RSU grant.

What transaction type is shown in the Bioventus (BVS) Form 4/A for Philip G. Cowdy?

The Form 4/A lists a derivative transaction coded "A" as a grant or award of 2,700 Restricted Stock Units. However, a footnote specifies that this grant was inadvertently reported and was not accepted, so it did not create an actual position.

Why is the Bioventus (BVS) Form 4/A labeled as an amendment?

It is an amendment because Bioventus previously filed a Form 4 on April 5, 2021, that incorrectly reported a Restricted Stock Unit grant. The amendment clarifies the grant was not accepted and that Cowdy had no Bioventus securities as of April 1, 2021.